Another possible Rx for #SLE: Phase Ib/IIa orelabrutinib (irrevers BTKi) for SLE shows promise. Improvement in SRI-4, SLEDAI2K, proteinuria, dsDNA, C3/C4; dec in IgG/M/Bcells. Safety: lymphopenia w/ORE #EULAR2022 LB0005 @rheumnow https://t.co/etZ9hMYNfn

#EULAR2022 POS0280 Gout is associated with higher mortality in Women ⭐️Higher all cause and CV mortality RR 1.28 risk of mortality in pts without CHD, with gout compared to controls (No CHD or gout) @Rheumnow https://t.co/6o1EKSp2F8

MIVAC I & II RCTs from India: for AZ vaccine (ChAdOx1), withhold MTX for 2w after: hold both dose 1&2 or hold just dose 2 (vs continue) Endpoint: Ab titre both hold approaches better than continue, to a similar magnitude - similar to German study w mRNA #EULAR2022 @RheumNow

Orelabrutinib Bruton’s tyrosine kinase inhibitor in SLE RCT phase Ib/IIa SRI(4) wk 12 50mg 50% 80mg 61% and 100mg 64% and 37.5% PBO Trend ⬇️ proteinuria, anti-dsDNA & IgG Safety: 3SAEs in OLE group LB0005 @RheumNow #EULAR2022 https://t.co/4r16NTaZvT

Sreekanth et al. 2 studies re holding MTX after both doses vs only 2nd dose of AZ COVID vaccine. Either holding strategy increased ab titres. Only holding 2nd non-inferior to holding both with decreased flares @RheumNow #EULAR2022 LB0003 https://t.co/aCOEdXp4ol https://t.co/XAZyBojryK

• EULAR Abstract Archive

#EULAR2022 LB0006 SAPHYR: P3 trial, 52 wk: Sarilumab in relapsing PMR Study terminated early due to COVID recruitment ⭐️Sustained remission: 28 vs 10%, primary endpt ⭐️HR of flare 0.56 on Sarilumab ⭐️Less steroid usage, glucocorticoid tox score @Rheumnow https://t.co/5PP1YP7YtU

#LB0006 #EULAR2022 Therapy for relapsing polymyalgia rheumatica. 118/280 recruited re:COVID impact. Phase 3 RCT of Sarilumab+14Wk Steroid taper showed more pts had sustained remission at Wk52 vs PBO+52Wk Steroid Taper(28% vs 10%) even if CRP excluded. PRO improved too! @RheumNow https://t.co/P11iXIAfGn

ECLIPSE UK primary care dataset: 23 million pts @DrMaxYates1 1. in >55yo, PMR prevalence 2.2% (10,000 new dx/y) 2. 1/4 take PNL for >4y (PMR = 18% of all pts on PNL) 3. mean 3.5 comorbid dx (steroids worsen) Now tell me we don't need better PMR therapies. #EULAR2022 @RheumNow

Does treating spondyloarthritis early matter? Systematic review showed in nr-axSpA tx with biologics may lead to better outcomes compared to established axSpA axSpA - no difference in response between early vs. established disease @RheumNow #EULAR2022 ABST#POS0302

#EULAR2022 LB003: W/d MTX w COVID vax MIVAC 1: hold MTX both vax vs continuing MIVAC 2: hold after 2nd dose only vs continuing ⭐️MTX hold: improved Ab titers, no diff in MIVAC1/2 ⭐️Higher reported flare for holding with both doses (36%) vs just 2nd dose (12%) @Rheumnow

Sarilumab in PMR SAPHYR Phase 3 RCT Underpowered (<50% target recruitment) -% remission sustained from wk12 to wk 52 28% vs 10% PBO -Risk of flare reduced HR 0.56 -Improvement of several PROs No new safety signal LB0006 @RheumNow #EULAR2022 https://t.co/n7WdQxQaHo

SAPHYR phase 3 RDBPCT study: #sarilumab vs PCB for relapsing #PMR on pred 7.5+ mg/d. Study met endpoints (whether of or not CRP was included). Time to first flare was longer w/SARI, less steroid use, and also better PROs. AE: #EULAR2022 LB0006 @rheumnow 1/2 https://t.co/lIspLKlveb

#LB0002 #EULAR2022 An interesting study design looking at flare rate following withdrawal of drug after WK12. Phase 3 RCT of Baricitinib in paediatric JIA showed 76% met ACR30 at WK12. The Double-blind withdrawal showed less patients on Bari flared vs PBO (17% vs 51%) @RheumNow https://t.co/T0mSDkoHJo

Ramanan et al Baricitinib in JIA. Double blind withdrawal study of prior responders. Earlier flare with PBO vs bari (HR 0.24 [95%CI 0.13,0.45], p<0.001. Less flares with bari vs PBO (17.1% vs 50.6%) p<0.001 @RheumNow #EULAR2022 LB0002 https://t.co/22rp70njRu https://t.co/LtJE9dz0GT

• EULAR Abstract Archive

Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX on joint, skin, QoL, function @RheumNow #EULAR2022 POS1059